Is Cara Therapeutics Stock a Buy After Its First FDA Drug Approval
Cara Therapeutics(NASDAQ:CARA) recently scored a key win with Food and Drug Administration approval of Korsuva in treating pruritis associated with chronic kidney disease for patients on hemodialysis. In this Motley Fool Live video recorded on Aug. 25,…
